tiprankstipranks
Trending News
More News >
Dyadic International Inc. (DYAI)
:DYAI
US Market
Advertisement

Dyadic International (DYAI) Earnings Dates, Call Summary & Reports

Compare
131 Followers

Earnings Data

Report Date
Mar 31, 2026
After Close (Confirmed)
Period Ending
2025 (Q4)
Consensus EPS Forecast
-0.05
Last Year’s EPS
-0.05
Same Quarter Last Year
Moderate Buy
Based on 1 Analysts Ratings

Earnings Call Summary

Q3 2025
Earnings Call Date:Nov 12, 2025|
% Change Since:
|
Earnings Call Sentiment|Neutral
The earnings call presented both advancements and challenges. Dyadic has achieved significant milestones, such as its first bulk sale and strategic partnerships, indicating positive momentum. However, the decrease in revenue and increased net loss highlight financial challenges. Overall, the sentiment is cautiously optimistic, with strong strategic positioning but immediate financial hurdles.
Company Guidance
During the call, Dyadic International, Inc. provided guidance on several key metrics and strategic directions for the company. The third quarter of 2025 marked a significant transition for Dyadic as it rebranded to Dyadic Applied Biosolutions, focusing on commercial growth with the first bulk sale of a Dyadic-produced protein and the anticipation of additional product opportunities emerging in 2025 and accelerating in 2026. Financially, the company reported a decrease in total revenue for Q3 2025 to $1.165 million from $1.958 million a year ago, attributed mainly to a drop in research and development and license and milestone revenues, partially offset by increased grant revenue. Operating expenses increased due to rebranding and business development efforts. The company closed a public offering raising approximately $4.9 million, and as of September 30, 2025, held $10.4 million in cash and equivalents. Dyadic also highlighted strategic partnerships, including a CRISPR licensing agreement with ERS Genomics to enhance genetic capabilities and a collaboration with Intralink to expand market reach in Asia. The company remains focused on life sciences and food nutrition segments, expecting growth from its recombinant protein platforms and continued advancement in its biopharmaceutical programs supported by non-dilutive funding.
First Commercial Bulk Sale
Dyadic International achieved its first commercial bulk sale of a Dyadic-produced protein, marking a pivotal transition from a platform-centric R&D organization to a commercially focused biotechnology company.
Rebranding and Website Relaunch
The company rebranded as Dyadic Applied Biosolutions and launched a redesigned corporate website to enhance commercial engagement.
CRISPR Cas9 Gene Editing License
Dyadic obtained a license for CRISPR Cas9 gene editing capabilities, enhancing strain optimization and productivity, which supports commercialization and profitability.
Milestone Payments from ProLiant
Dyadic received a total of $1.5 million in milestone payments from ProLiant, including a third payment of $500,000 in October, signifying progress in the recombinant human albumin program.
Partnership with Intralink
Dyadic partnered with Intralink to accelerate market penetration in Japan and South Korea, expanding their global market reach efficiently.

Dyadic International (DYAI) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

DYAI Earnings History

Report Date
Fiscal Quarter
Forecast / EPS
Last Year's EPS
EPS YoY Change
Press Release
Slides
Play Transcript
Mar 31, 2026
2025 (Q4)
-0.04 / -
-0.05
Nov 12, 2025
2025 (Q3)
-0.04 / -0.06
-0.01-500.00% (-0.05)
Aug 13, 2025
2025 (Q2)
-0.06 / -0.06
-0.0714.29% (+0.01)
May 14, 2025
2025 (Q1)
- / -0.07
-0.070.00% (0.00)
Mar 26, 2025
2024 (Q4)
-0.04 / -0.05
-0.0837.50% (+0.03)
Nov 12, 2024
2024 (Q3)
-0.07 / -0.01
-0.0683.33% (+0.05)
Aug 13, 2024
2024 (Q2)
-0.07 / -0.07
-0.070.00% (0.00)
May 14, 2024
2024 (Q1)
- / -0.07
-0.03-133.33% (-0.04)
Mar 28, 2024
2023 (Q4)
-0.07 / -0.08
-0.07-14.29% (>-0.01)
Nov 08, 2023
2023 (Q3)
-0.06 / -0.06
-0.060.00% (0.00)
The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.
Beat
Missed

DYAI Earnings-Related Price Changes

Report Date
Price 1 Day Before
Price 1 Day After
Percentage Change
Nov 12, 2025
$0.94$0.90-4.26%
Aug 13, 2025
$0.82$0.80-2.44%
May 14, 2025
$1.04$1.00-3.85%
Mar 26, 2025
$1.33$1.35+1.50%
Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does Dyadic International Inc. (DYAI) report earnings?
Dyadic International Inc. (DYAI) is schdueled to report earning on Mar 31, 2026, After Close (Confirmed).
    What is Dyadic International Inc. (DYAI) earnings time?
    Dyadic International Inc. (DYAI) earnings time is at Mar 31, 2026, After Close (Confirmed).
      Where can I see when companies are reporting earnings?
      You can see which companies are reporting today on our designated earnings calendar.
        What companies are reporting earnings today?
        You can see a list of the companies which are reporting today on TipRanks earnings calendar.
          What is DYAI EPS forecast?
          DYAI EPS forecast for the fiscal quarter 2025 (Q4) is -0.05.
            What am I Missing?
            Make informed decisions based on Top Analysts' activity
            Know what industry insiders are buying
            Get actionable alerts from top Wall Street Analysts
            Find out before anyone else which stock is going to shoot up
            Get powerful stock screeners & detailed portfolio analysis